Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05735925
Other study ID # 2022-A02408-35
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2023
Est. completion date July 2023

Study information

Verified date February 2023
Source Association pour la Recherche Clinique et Immunologique
Contact Sophie GILIBERT, PhD
Phone +33 6 65 37 50 08
Email sophie.gilibert@lyonrechercheclinique.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hidradenitis Suppurativa (HS) is a chronic disabling inflammatory skin disorder associated with the development of painful and purulent lesions of the folds (armpits, inguinal folds, sub-mammary glands). HS most often develops in adolescence or young adulthood and is characterized by inflammation of the pilo-sebaceous system, of progressive severity (folliculitis, nodule, abscess, fistula). The pathogenesis of HS is still poorly understood: the fact that patients respond to combinations of antibiotics and/or immunosuppressive treatments suggests that the disease could be due to a dysregulated immune response against microbial skin flora. Unconventional lymphocytes (UL), classically considered being at the interface of innate and adaptive immunity, play an important role in immune protection against microbial flora. But UL dysfunction has also been reported in many autoimmune diseases involving various tissues (joints, digestive tract, skin). The uncontrolled and chronic activation of these UL by skin microbiota could therefore play a role in the pathogenesis of HS.


Description:

The aim of this exploratory study is to analyze the interplay between microbiota and the innate and adaptative immune response in the pathogenesis of HS. To better understand this host-microbiota interplay, we will assess the number, frequency and functional phenotypes of the different lymphocyte subsets in HS patients, with a special focus regarding the UL. In the same time, we will assess the diversity and nature of skin microbiota of the same patients. Finally, we will explore the relation between the immune response and the skin microbiota in HS, using correlation analysis (Spearman coefficient). In this study, HS patients will be their own control for leucocyte phenotyping, cytokine analysis and T Cells Receptor (TCR) sequencing (skin biopsies) and for skin microbiota analysis. Paired (age/sex) healthy volunteers will be controls for gut microbiota analysis and for immunophenotyping of circulating leukocytes (Peripheral Blood Mononuclear Cells (PBMC) analysis).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date July 2023
Est. primary completion date July 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subject able to read, understand and give documented informed consent - Subject willing and able to comply with the protocol requirements for the duration of the study - Subject with health insurance coverage according to local regulations - For woman with childbearing potential, negative pregnancy test at the inclusion visit Specific criteria for HS patients - Subject diagnosed with HS for at least 6 months - Subject diagnosed with moderate-to-severe HS defined by HS PGA=3 - Subject presenting an HS with inflammatory phenotype defined by the presence of folliculitis, nodules and/or abcesses - Subject suffering from at least 4 flares/year and presenting 5 active inflammatory lesions (nodules and/or abcesses) Exclusion Criteria: - Pregnancy or breast-feeding women - Subject treated by allergen immunotherapy within 4 weeks before inclusion - Subject treated by Non-Steroidal Anti-Inflammatory Drugs (NSAID), antibiotics or proton-pump inhibitors within 4 weeks before inclusion - Subject treated by live (attenuated) vaccine within 4 weeks before inclusion - Subject treated by anti-viral treatment within 4 weeks before inclusion - Subject treated by anti-diarrhea treatment including, but not limited to Loperamide - Subject treated by immunosuppressive/immunomodulatory substances including oral corticosteroid or biological agents within 4 weeks before inclusion - Subject presenting spondylo-arthritis or Inflammatory Bowel Disease (IBD) - Subject with a Body Mass Index (BMI)<18.5 or BMI>35 - Subject consuming probiotics or using a specific diet (e.g. gluten free, vegetarian, vegan, intermittent fasting) - Subject with any additional condition that, in the opinion of the investigator, may interfere with the assessment or put the subject at risk - Linguistic or mentally incapacity to sign the consent form - Subject protect by the law (adult under guardianship, or hospitalized in a public or private institution for a reason other than study, or incarcerated) - Subject in an exclusion period from a previous study or who is participating in another clinical trial using a drug Specific criteria for HS patients - Subject currently experiencing or having a history of other concomitant skin conditions that would interfere with evaluation of HS - History of allergic reaction to local anesthetic product - History of wound healing disorders (e.g. hypertrophic scars, keloids) - History of extensive armpit surgery - Subject with known active infection to Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) - Subject treated for their HS by systemic therapy, investigational or commercial, approved or off label) - Subject treated for their HS by immunosuppressants or intralesional corticosteroids within 4 weeks before the inclusion - Subject treated for their HS by topical antibiotics within 4 weeks before the inclusion - Subject previously treated with monoclonal antibodies

Study Design


Intervention

Diagnostic Test:
Skin Swab & Skin Biopsies & Blood Sample
These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients

Locations

Country Name City State
France Department of Dermatology-Hôpital Edouard Herriot Lyon Rhône

Sponsors (1)

Lead Sponsor Collaborator
Association pour la Recherche Clinique et Immunologique

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of the different leucocytes subsets Number of the different leucocytes subsets (unconventional and conventional lymphocytes) in the lesional skin versus non lesional skin Number of the different leucocytes subsets (unconventional and conventional lymphocytes) in the blood of HS patients versus healthy volunteers Day 0
Primary Frequency of the different leucocytes subsets Frequency of the different leucocytes subsets (unconventional and conventional lymphocytes) in the lesional skin versus non lesional skin Frequency of the different leucocytes subsets (unconventional and conventional lymphocytes) in the blood of HS patients versus healthy volunteers Day 0
Primary Functional phenotype of the different leucocytes subsets Functional phenotype of the different leucocytes subsets (unconventional and conventional lymphocytes) in the lesional skin versus non lesional skin Functional phenotype of the different leucocytes subsets (unconventional and conventional lymphocytes) in the blood of HS patients versus healthy volunteers Day 0
Secondary Quantitative RNA Quantitative RNA expression of selected cytokines' genes in the lesional skin versus non lesional skin Day 0
Secondary TCR Sequencing TCR sequencing in the lesional skin versus non-lesional skin
TCR sequencing in the blood of HS patients versus healthy volunteers
Correlation between lesional skin and blood clones in the same patient will be searched
Day 0
Secondary Bacterial diversity Bacterial diversity of microbes from skin flora in lesional skin versus non lesional skin Day 0
Secondary Bacterial abundance Bacterial abundance of microbes from skin flora in lesional skin versus non lesional skin Day 0
Secondary Bacterial diversity Bacterial diversity of microbes from gut flora in HS patients versus healthy volunteers Day 14
Secondary Bacterial abundance Bacterial abundance of microbes from gut flora in HS patients versus healthy volunteers Day 14
Secondary Presence of bacterial DNA translocation Presence of bacterial DNA translocation in the blood of HS patients Day 0
Secondary Description of bacterial DNA translocation Genus, phyla, species, specific bacteria abundance and overall diversity in the blood of HS patients Day 0
See also
  Status Clinical Trial Phase
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT02896920 - Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
Completed NCT01468233 - Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Phase 3
Completed NCT01468207 - Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Phase 3
Completed NCT03894956 - Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
Completed NCT03001115 - Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
Not yet recruiting NCT05723757 - Autophagy Dysfunction in Hidradenitis Suppurativa N/A
Completed NCT02808975 - Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically Phase 4
Completed NCT04430855 - A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms Phase 2
Recruiting NCT06212999 - A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Phase 3
Active, not recruiting NCT04354012 - Hidradenitis Suppurativa Wound Care Phase 2
Completed NCT03487276 - Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Recruiting NCT05620836 - A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 3
Recruiting NCT05620823 - A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Phase 3
Recruiting NCT06241573 - A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab Phase 2/Phase 3
Available NCT05583604 - Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)